1. Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study. (14th June 2018) Authors: Sato, Nobuaki; Masuda, Norikazu; Morimoto, Takashi; Ueno, Takayuki; Kanbayashi, Chizuko; Kaneko, Koji; Yasojima, Hiroyuki; Saji, Shigehira; Sasano, Hironobu; Morita, Satoshi; Ohno, Shinji; Toi, Masakazu Journal: Cancer medicine Issue: Volume 7:Number 7(2018:Jul.) Page Start: 3044 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study. (30th July 2019) Authors: Sato, Nobuaki; Masuda, Norikazu; Morimoto, Takashi; Ueno, Takayuki; Kanbayashi, Chizuko; Kaneko, Koji; Yasojima, Hiroyuki; Saji, Shigehira; Sasano, Hironobu; Morita, Satoshi; Ohno, Shinji; Toi, Masakazu Journal: Cancer medicine Issue: Volume 8:Number 12(2019:Sep.) Page Start: 5468 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study. (8th January 2021) Authors: Tsuda, Hitoshi; Yoshida, Masayuki; Akiyama, Futoshi; Ohi, Yasuyo; Kinowaki, Keiichi; Kumaki, Nobue; Kondo, Yuzuru; Saito, Akihisa; Sasaki, Eiichi; Nishimura, Rieko; Fujii, Satoshi; Homma, Keiichi; Horii, Rie; Murata, Yuya; Itami, Makiko; Kajita, Sabine; Kato, Hiroyuki; Kurosumi, Masafumi; Sakatan... Journal: Japanese journal of clinical oncology Issue: Volume 51:Number 3(2021) Page Start: 434 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗